Abstract: An embodiment solid electrolyte includes a first compound and a second compound. The first compound is represented by a first chemical formula Li7-aPS6-a(X11-bX2b)a, wherein X1 and X2 are the same or different and each represents F, Cl, Br, or I, and wherein 0<a?2 and 0<b<1, and the second compound is represented by a second chemical formula Li7-cP1-2dMdS6-c-3d(X11-eX2e)c, wherein X1 and X2 are the same or different and each represents F, Cl, Br, or I, wherein M represents Ge, Si, Sn, or any combination thereof, and wherein 0<c?2, 0<d<0.5, and 0<e<1.

Abstract: Proposed is a dual band RFID tag including a first rectifier configured to receive and rectify a first RF signal modulated at a first frequency, a first regulator configured to regulate an output voltage of the first rectifier, a second rectifier configured to receive and rectify a second RF signal modulated at a second frequency, a second regulator configured to regulate an output voltage of the second rectifier, a voltage distributor connected to a first node and a ground in a state of being positioned therebetween, the output terminal of the first rectifier and the output terminal of the second rectifier being both connected to the first node, a multiplexer configured to output any one of an analog detection signal output from a sensor and an output signal of the voltage distributor, in response to a first selection signal or a second selection signal, and an analog-to-digital converter configured to receive as an operating voltage a voltage of a second node to which an output terminal of the first regulat

Abstract: In various embodiments, an antenna array may comprise a dielectric; a first patch antenna disposed on a first region of the dielectric; a second patch antenna disposed on a second region of the dielectric; and a ground layer including a first sub-ground layer in contact with a lower portion of the first region of the dielectric, a third sub-ground layer in contact with a lower portion of the second region of the dielectric, and a second sub-ground layer spaced apart from a lower portion between the first region and the second region of the dielectric.

Abstract: Provided is a DNA aptamer specifically binding to an insulin receptor, a pharmaceutical composition for treating diabetes including the same, and a composition for diagnosing diabetes including the DNA aptamer. The insulin receptor aptamer may be effectively used in compositions for preventing or treating insulin-related diseases due to better downstream signaling activity of the insulin receptor than insulin or existing insulin receptor aptamers conventionally used for treatment of insulin-related diseases such as diabetes.

Abstract: The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.

Abstract: The present invention relates to a DNA aptamer specifically binding to a hepatocellular carcinoma-related Glypican-3 (GPC3) protein, treatment of cancers related to the Glypican-3 protein using the same, a composition for inhibiting a cancer and a composition for diagnosing a cancer comprising the same as an active ingredient.

Abstract: The present invention relates to a DNA aptamer specifically binding to a hepatocellular carcinoma-related Glypican-3(GPC3) protein, treatment of cancers related to the Glypican-3 protein using the same, a composition for inhibiting a cancer and a composition for diagnosing a cancer comprising the same as an active ingredient.

Abstract: The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.

Abstract: The present invention relates to a composition for preventing and treating metabolic disorders, containing a water extract of Pleurotus eryngii var. ferulea (Pf) as an active ingredient, wherein the water extract of Pleurotus eryngii var. ferulea (Pf) has a remarkable effect of being able to be used as a pharmaceutical composition or functional health food for preventing or treating obesity or diabetes by confirming the functionality whereby fat accumulation and blood glucose increase generated when taking a high fat diet can be inhibited.

Abstract: The present invention relates to a method for analyzing the pattern of live intercellular membrane protein binding. The method for analyzing the pattern according to the present invention can analyze accurately, sensitively, quickly, and readily the binding pattern of a target membrane protein and a candidate substance to be specifically bound therewith without tagging to a ligand, and thus measure directly and accurately the position and quantitative information of the binding of the membrane protein and the target substance. Such effects make it possible to apply the method for various uses such as dissociation constant, mutant study, complex formation, and signal transduction. Moreover, it is expected to use the method for searching out undiscovered membrane proteins and target substances.

Abstract: This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.

Abstract: A method of collecting information of interest to a user regarding multimedia content is described. The method may include receiving first content about the information of interest to the user among the multimedia content, collecting metadata of the first content by using a uniform resource identifier (URI) of the first content, extracting at least one first information object including a schema according to a search category from the metadata, and storing the first information object in a first database.

Abstract: A method and apparatus for locating a mobile terminal by use of messages received to the mobile terminal are provided. The mobile terminal locating method may include creating at least one location related candidate for the mobile terminal by use of a message that is received to the mobile terminal, and determining a location of the mobile terminal by matching the created location related candidate to stored place information. The current location of the mobile terminal may be recognized by simply analyzing the received messages without the need for installation of additional device on the mobile terminal.

Abstract: The present invention relates to a composition for the treatment or prevention of obesity, the composition containing water extracts of Fomitella fraxinea as an active ingredient, and to a medicine and a dietary supplement, containing the extracts.

Abstract: Provided is a pharmaceutical composition for preventing or treating diabetic nephropathy, comprising a tensin like C1 domain containing phosphatase (TENC1) inhibitor as an active ingredient. A new target for treating diabetic nephropathy is presented by confirming that TENC1 expression is increased in kidney tissue of diabetes or a podocyte cell line to which a high blood glucose environment is given and experimentally proving that nephrin phosphorylation inhibited by the PTPase activity of TENC1 affects the permeability and mTORC1 signaling of the podocytes resulting in inducing podocyte hypertrophy.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1.

Abstract: The present invention relates to a method for analyzing the pattern of live intercellular membrane protein binding. The method for analyzing the pattern according to the present invention can analyze accurately, sensitively, quickly, and readily the binding pattern of a target membrane protein and a candidate substance to be specifically bound therewith without tagging to a ligand, and thus measure directly and accurately the position and quantitative information of the binding of the membrane protein and the target substance. Such effects make it possible to apply the method for various uses such as dissociation constant, mutant study, complex formation, and signal transduction. Moreover, it is expected to use the method for searching out undiscovered membrane proteins and target substances.

Abstract: The present invention relates to a method for preparing a target-specific non-antibody protein, and more particularly, to a method for preparing a target-specific non-antibody protein comprising the steps of: selecting non-antibody proteins having a structural complementarity with the target site of a target protein in a non-antibody protein library; calculating a binding energy of the selected non-antibody protein and the target protein; selecting a non-antibody protein having a favorable binding energy among the selected non-antibody proteins; selecting amino acid residues having a high binding energy among the interfacial amino acid residues of the selected non-antibody protein and the target protein; and substituting the selected amino acid residues with the amino acid residues having a low binding energy.

Abstract: The present invention relates to DNA aptamer specifically binding to integrin ?v?3, and a composition for diagnosis of cancer or cancer metastasis comprising the same as an active ingredient. And, the present invention relates to a composition for imaging tumor regions comprising the aptamer, and a contrast medium comprising the same.

Abstract: This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.